Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

National Taiwan University Hospital, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Goethe University Frankfurt, University Medical Center of the Johannes Gutenberg University Mainz, Johannes Gutenberg University Mainz, Royal Marsden Hospital, Wakayama Medical University, Shanghai Pulmonary Hospital, Tongji University, Central South University, Xiangya Hospital Central South University, Queensland University of Technology, Princess Alexandra Hospital, Jiangsu Cancer Hospital, Shanghai Chest Hospital, Shanghai Jiao Tong University, Kunming Medical University, Prince of Songkla University, Konkuk University Medical Center, Chungbuk National University Hospital, Taipei Veterans General Hospital, McGill University, Institut de Cancérologie de l'Ouest, First Pavlov State Medical University of St. Petersburg, Chinese University of Hong Kong, Royal Prince Alfred Hospital, National Cheng Kung University Hospital, National Cheng Kung University, Kanagawa Cardiovascular and Respiratory Center, Boehringer Ingelheim (United Kingdom), Harvard University, Massachusetts General Hospital